JQ1 has demonstrated antileukemic effects in vitro against a variety of human AML cell lines and primary patient samples [29, 41, 42], as well as in vivo against human AML xenografts [41] and murine MLL/AF9; KrasG12D transplants [29]. This evidence concerns the gene KMT2A and acute myeloid leukemia.